Association of Elevated Serum Lipoprotein(a), Inflammation, Oxidative Stress and Chronic Kidney Disease with Hypertension in Non-diabetes Hypertensive Patients

被引：8

作者：

Tangvarasittichai S. ^{[1
]}

Pingmuanglaew P. ^{[2
]}

Tangvarasittichai O. ^{[1
]}

机构：

[1] Chronic Disease Research Unit, Department of Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok

[2] Department of Community Occupational Family Medicine, Faculty of Medicine, Naresuan University, Phitsanulok

来源：

Indian Journal of Clinical Biochemistry | 2016年 / 31卷 / 4期

关键词：

Chronic kidney disease; hs-CRP; Hypertension; Lipoprotein(a); Malondialdehyde;

D O I：

10.1007/s12291-016-0553-1

中图分类号：

学科分类号：

摘要：

Hypertension is the most common cardiovascular risk factor. Lipoprotein(a) [Lp(a)], inflammation, oxidative stress and chronic kidney disease (CKD) exacerbate the response to tissue injury and acts as markers of the vascular disease, especially in glomerulosclerosis. We compared the clinical characteristics of 138 non-diabetes hypertensive women (ndHT) patients with 417 non-diabetes normotensive subjects and tested the association of hypertension with Lp(a), inflammation, CKD and oxidative stress by using multiple logistic regression. BP, BMI, waist circumference, creatinine, Lp(a), inflammation and malondialdehyde levels were significantly higher and CKD state in the ndHT patients (p < 0.05). Multiple logistic regression showed hypertension associated with increased Lp(a), inflammation, ORs and 95 % CIs were 2.52 (1.33, 4.80), 2.75 (1.44, 5.27) after adjusting for their covariates. Elevated serum Lp(a) and inflammation levels concomitants with increased oxidative stress and CKD were the major risk factors associated with hypertension and implications for the increased risk of HT and vascular disease. © 2016, Association of Clinical Biochemists of India.

引用

页码：446 / 451

页数：5

共 32 条

[1]

Catena C., Novello M., Lapenna R., Baroselli S., Colussi G., Nadalini E., Et al., New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a), J Hypertens, 23, pp. 1617-1631, (2005)

[2]

Sechi L.A., Catena C., Casaccio D., Zingaro L., Lipoprotein(a), haemostatic variables, and cardiovascular damage in hypertensive patients, J Hypertens, 18, pp. 709-716, (2000)

[3]

Sechi L.A., Zingaro L., Catena C., Perin A., De Marchi S., Bartoli E., Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure, Kidney Int, 56, pp. 1049-1057, (1999)

[4]

Scanu A.M., Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications, Curr Atheroscler Rep, 5, pp. 106-113, (2003)

[5]

Terres W., Tatsis E., Pfalzer B., Beil F.U., Beisiegel U., Hamm C.W., Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a), Circulation, 91, pp. 948-950, (1995)

[6]

Collaboration E.R.F., Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., Et al., Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, pp. 412-423, (2009)

[7]

He J., Whelton P.K., Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease, J Hypertens Suppl, 17, pp. S7-S13, (1999)

[8]

Marcantoni C., Jafar T.H., Oldrizzi L., Levey A.S., Maschio G., The role of systemic hypertension in the progression of nondiabetic renal disease, Kidney Int Suppl, 75, pp. S44-S48, (2000)

[9]

Lee L.K., Meyer T.W., Pollock A.S., Lovett D.H., Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney, J Clin Invest, 96, pp. 953-964, (1995)

[10]

Gazzaruso C., Buscaglia P., Garzaniti A., Bonetti G., Savino S., Mariotti S., Et al., Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension, J Cardiovasc Risk, 3, pp. 191-197, (1996)

← 1 2 3 4 →